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ChemotherapyProtein kinases (PKs) are one of the largest protein families in most eukaryotic organisms. These enzymes
are involved in the control of cell proliferation, differentiation and metabolism and a large number of the
anticancer drugs currently used are directed against PKs. The structure and function of PKs are well con-
served throughout evolution. In schistosome parasites, PKs were shown to be involved in essential func-
tions at every stage of the parasite life cycle, making these enzymes promising anti-parasite drug targets.
In this study, we tested a panel of commercial inhibitors for various PKs and analyzed their effects on
pairing and egg production by schistosomes as well as their toxicity towards schistosomula larvae.
Results obtained conﬁrmed the deleterious effect of PK targeting on Schistosoma mansoni physiology
and the important function of different tyrosine and serine/threonine kinases in the biology and repro-
duction of this parasite. They also indicated for the ﬁrst time that the Protein kinase B (also called Akt)
which is a major downstream target of many receptor tyrosine kinases and a central player at the cross-
roads of signal transduction pathways activated in response to growth factors and insulin, can constitute
a novel target for anti-schistosome chemotherapy. Structural and functional studies have shown that
SmAkt is a conserved kinase and that its activity can be inhibited by commercially available Akt inhibi-
tors. In treated adult worms, Akt/PKB kinase pathway inhibitors induced profound alterations in pairing
and egg laying and they also greatly affected the viability of schistosomula larvae.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Schistosomiasis is a disease with major medical and economic
importance affecting human and cattle. It is the second major par-
asitic disease after malaria with more than 230 million individuals
infected in the world, and a number of annual deaths estimated to
200 thousands (Colley et al., 2014). Chemotherapy of schistosomi-
asis relies on a single drug, Praziquantel (PZQ), which efﬁciently
reduces morbidity and mortality due to the disease. However,
mass treatment has raised concerns regarding the emergence of
resistance to this drug (Doenhoff and Pica-Mattoccia, 2006; Pica-
Mattoccia et al., 2009; Melman et al., 2009). This has motivated
the search for alternative treatments and intensive efforts have
been made during last years to identify novel molecular targetsfor chemotherapy (Doenhoff et al., 2008; DeMarco and Verjovski-
Almeida, 2009).
Protein kinases (PKs) are one of the largest protein families in
most eukaryotic organisms. PKs are involved in the control of cell
proliferation, differentiation and metabolism and these druggable
enzymes are well conserved throughout evolution. Their biochem-
ical characteristics are well studied due to their importance in can-
cer, and a large variety of small molecules targeting selectively
kinase activities is now commercially available and already used
for human cancer therapy (Johnson, 2009). In schistosomes, many
studies have shown that PKs are implicated in essential functions
at every stage of the parasite life cycle, and that these enzymes
represent suitable anti-parasite drug targets (Dissous et al., 2007,
2014a; Dissous and Grevelding, 2011; Beckmann et al., 2012).
Tyrosine Kinases (TKs) have been considered as good candidates
because of their essential roles in development and metabolism
(Dissous et al., 2006, 2007; Dissous and Grevelding, 2011). The
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(RTKs) and 19 cytosolic TKs (CTKs) (Andrade et al., 2011; Avelar
et al., 2011). Receptor TKs (RTKs) regulate many cellular activities
such as proliferation, migration or differentiation, and they are the
ﬁrst actors in TK signaling, being able to integrate perception,
response to extracellular signals and propagation by phosphoryla-
tion of intracellular targets (Hubbard and Till, 2000). Seven RTK
molecules have been studied for their role in the control of parasite
development and/or reproduction processes. SER (Schistosoma Epi-
dermal growth factor Receptor) plays potential role in host–para-
site interactions, and parasite growth and reproduction (Vicogne
et al., 2004). Two insulin receptors (IR) are involved, respectively,
in regulating sugar uptake and growth of schistosomes (Khayath
et al., 2007; Ahier et al., 2008). Recently, two Venus Kinase Recep-
tors (VKR), that belong to a novel family of RTKs (discovered for the
ﬁrst time in schistosomes) (Vicogne et al., 2003; Vanderstraete
et al., 2013a; Dissous et al., 2014b) and that possess a TK domain
similar to that of IR (Ahier et al., 2009; Gouignard et al., 2012),
were demonstrated to control parasite reproductive activities
(Vanderstraete et al., 2014). Also, two proteins of the FGFR (Fibro-
blast Growth Factor Receptor) family could participate with these
RTKs in the development of reproductive organs (Hahnel et al.,
2014; Morel et al., 2014). All these schistosome RTKs can be inhib-
ited by commercially available kinase inhibitors as well as the non-
receptor CTKs that participate to their downstream signaling. Par-
ticularly, three schistosome CTKs-SmTK3 (Src kinase (Kapp et al.,
2004)), SmTK4 (Syk kinase (Knobloch et al., 2002)) and SmTK6
(Src/Abl-like kinase (Beckmann et al., 2011))-presumably act in a
multikinase complex and their participation to RTK signaling can
be inhibited by speciﬁc TK inhibitors (Beckmann et al., 2011).
Besides the importance of TK proteins as druggable enzymes, a
large number of kinases phosphorylating Serine/Threonine (S/T)
residues have been characterized in schistosomes and some of
them were described as potential targets against these parasites.
Particularly, biochemical approaches and functional screening of
activin/TGFb receptor, Polo, Ste 20, MAPK (Mitogen-Activated
Protein Kinase) (ERK, p38 and JNK), MEK (Mitogen/Extracellular
signal-regulated Kinase) and AGC (PKC (Ca-dependent protein
kinase C) and PKA (cyclic AMP-dependent protein kinase)) kinase
families have supported the roles of S/T kinases in cell prolifera-
tion, motor activity and reproduction. Evidence has been obtained
that TGF-b pathways play a major role in female reproductive
development and egg embryogenesis (Knobloch et al., 2006;
Loverde et al., 2007; LoVerde et al., 2009; Buro et al., 2013). Inhibi-
tion of SmPlk1 (the schistosome Polo-like kinase homolog of the
major mitotic kinase overexpressed in many human tumors
(Strebhardt, 2010)) by the anticancer compound BI2536 caused
profound alterations of the reproductive organs in males and
females in vitro, including a reduction of gamete production
(Long et al., 2010). Pharmacological modulation of ERK activity in
adult worms using the MEK inhibitor, U0126, disturbed signiﬁ-
cantly the physiology of parasites and the PKC inhibitor,
GF109203X, was shown to inhibit worm pairing, egg output, and
ventral sucker attachment (Ressurreição et al., 2014). PKC belongs
to the AGC group of kinases which are cytoplasmic serine/threo-
nine kinases regulated by secondary messengers such as cyclic
nucleotide AMP (for PKA) or GMP (for PKG) or by lipids (for PKC
and PKB also called Akt). RNAi experiments in combination with
PKA inhibitors H-89 or PKI 14–22 amide have demonstrated the
importance of PKA activity for schistosome viability and egg pro-
duction (Swierczewski and Davies, 2009, 2010) and interference
with the PKG activity of the S. mansoni SmcGK by a cGMP analog
induced slow motion and reduced egg production by schistosomes
(Leutner et al., 2011). However, the role of PKB/Akt proteins in via-
bility and fertility of schistosomes has not been described.Akt/PKB kinases are attractive targets for drug discovery due to
their key role in tumor cell survival or proliferation and to their
overexpression or activation in many cancers. Small molecule
inhibitors targeting the Akt signaling pathway are very promising
therapeutics against cancer (Kumar and Madison, 2005; Pal et al.,
2010). In this study, we have tested a new panel of commercial
inhibitors for various PKs and we analyzed their effects on pairing
and egg production by schistosomes as well as their toxicity
towards schistosomula larvae of S. mansoni. Results conﬁrmed
the deleterious effect of targeting PKs on schistosome physiology
and indicated that signaling of SmAkt, the PKB/Akt homolog of
S. mansoni, can constitute a novel potential target for anti-
schistosome chemotherapy. Structural and functional studies have
shown that SmAkt is a conserved kinase and that its activity can be
inhibited by commercially available Akt inhibitors. Three of these
inhibitors induced profound alterations in pairing and egg laying
in treated worms and they also greatly affected the viability of
schistosomula.2. Materials and methods
2.1. Parasite material
A Puerto-Rican strain of S. mansoni was maintained by passage
through albino Biomphalaria glabrata snails and Mesocricetus aura-
tus golden hamsters. Adult schistosomes were collected by portal
perfusion from infected hamsters at 42–45 days p.i. Schistosomula
were prepared as described previously (Dissous et al., 1981).
Experiments with hamsters infected by cercariae were performed
in accordance with the European Convention for the Protection of
Vertebrate Animals used for Experimental and other Scientiﬁc Pur-
poses (ETS No. 123; revised Appendix A) and were approved by the
committee for ethics in animal experimentation of the region Nord
Pas de Calais France (authorisation No. AF/2009) in the local animal
house of the Pasteur Institute of Lille (Agreement No. A59-35009).
2.2. In silico analyzes
Sequences were analyzed using the LASERGENE package (DNA-
Star, Madison, WI, USA). tBLASTn and BLASTn analyzes were per-
formed using the NCBI databank http://blast.ncbi.nlm.nih.gov.
gate2.inist.fr/Blast.cgi. Akt/PKB, PKA and PKC protein sequences
were aligned using ClustalW algorithm in the BioEdit v7.1 soft-
ware, and manually corrected. Neighbor-Joining trees were built
using MEGA5 (Tamura et al., 2011) under the JTT model, with
1000 bootstrap repetitions.
2.3. Protein kinase inhibitors
The InhibitorSelect™ 96-Well Protein Kinase Inhibitor Library I
from Calbiochem consists of 80, well-characterized, cell-perme-
able, potent and reversible protein kinase inhibitors. Each inhibitor
was provided in solution in DMSO at a concentration of 10 mM
(except the PI3K inhibitor E10 provided at 5 mM).
2.4. Treatment of cultured adult worms with inhibitors
Ten pairs of adult S. mansoniwere incubated for 72 h at 37 C in a
5% CO2 atmosphere in 6-well plates containing 2 mL of M199 med-
ium (Invitrogen) supplementedwith HEPES 10 mM, pH 7.4, penicil-
lin (50 U/mL), streptomycin (50 lg/mL), gentamycin (15 lg/mL),
rifampicin (60 lg/mL) and 10% fetal calf serum (Gibco) (hereafter
referred as M199 complete medium) in the presence of each
compound of the inhibitor library at 10 lM ﬁnal concentration.
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ing from 10 nM to 10 lM. Medium containing eggs was harvested
everyday and replaced by fresh medium with inhibitors. Medium
fractions were pooled and their content in eggs was determined
after centrifugation. The number of paired couples was estimated
every day by stereomicroscopy.
2.5. Treatment of schistosomula larvae with inhibitors
500 schistosomula were incubated for 72 h in 48-well plates
containing 500 lL of M199 complete medium with different con-
centrations (from 50 nM to 10 lM) of A4, A7 and A8 compounds.
Culture mediumwith inhibitors was refreshed daily. Parasite death
was assessed optically under microscope each day using three cri-
teria: absence of motility, tegument defects and granular appear-
ance. A minimum of 300 larvae was observed for each condition,
and the ratio dead/total larvae was calculated.
2.6. Molecular cloning of S. mansoni Akt
A putative S. mansoni Akt sequence was identiﬁed in Genbank
(XM_002578520.1) by tBLASTp analyzes of the S. mansoni genome
data bases (Berriman et al., 2009). 50 and 30 UTR were determined
with the SmAkt encoding ESTs AM042871.1, CF497410.2,
AA169931.1 and CF498818.1. The cDNA sequence of SmAkt was
obtained by PCR ampliﬁcation of total cDNA obtained from adult
S. mansoni RNA (prepared using TRIzol reagent, Invitrogen) by
reverse transcription using the Superscript III (Invitrogen). The
SmAkt sequence was ampliﬁed using SmAktFLf (50-CGGCACGA
GGCCAAGTCTTAAATGCTAGT-30) and SmAktFLr (50-GTTAAATCAT
GTTGGTGGCAGTCAATTGAACT-30) primers, cloned into a pCR2.1
TOPO cloning vector (Invitrogen) and sequenced (EuroﬁnsDNA).
A second PCR was performed using as primers SmAktFLRE-f (50-
CCggatccGTTATCGAGATTGCAGATTTTCTGGG-30) and SmAktFLRE-r
(50-GCctcgagAAAATGTGTCACCAAAACTATAACCAC-30) containing,
respectively, BamHI and XhoI restriction sites and the fragment
was inserted in frame in the pcDNA3.1-V5/His expression vector
(Invitrogen). Site-directed mutagenesis was performed on the
wild-type (WT) SmAkt construct to produce SmAkt E117K and
SmAkt L150R active mutants using, respectively, the 50-GGCTTA
TGAAACGCGGCAAACATATTAAAAATTGGCGACG-30 and 50-TAAAG
ATGATATGGCGCAACCTCGAAATAATTTTACTGTTCGCG-30 mutated
sequences and their reverse complement as primers.
2.7. Protein expression in Xenopus oocytes
cRNAs encoding SmAkt WT, E117K and L150R were synthesized
in vitro using the T7 mMessage mMachine kit (Ambion) and the
different SmAkt-pcDNA3.1-V5/His plasmids linearized by SphI as
templates. cRNAs were injected in stage VI Xenopus laevis oocytes
according to the procedure described previously (Vicogne et al.,
2004). Each oocyte was injected with 60 nL (60 ng) of cRNA in
the equatorial region and incubated at 19 C in ND96 medium
(96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM Hepes
pH 7.4 supplemented with 50 lg/mL Streptomycin/Penicillin,
225 lg/mL sodium pyruvate, 30 lg/mL trypsin inhibitor). For
inhibitor assays, oocytes were incubated with compounds (A4–8)
from the library I (Calbiochem) at different concentrations. After
15 h, germinal vesicle breakdown (GVBD) was detected by the
appearance of a white spot at the center of the animal pole of
the oocyte.
2.8. Immunoprecipitation and Western blot analyzes
Expression and phosphorylation of SmAkt proteins in oocytes
were conﬁrmed by immunoprecipitation of oocyte lysatesaccording to the procedure described previously (Vicogne et al.,
2004). Following 15 h of expression, oocytes were lysed in buffer
A (50 mM Hepes pH 7.4, 500 mM NaCl, 0.05% SDS, 5 mM MgCl2,
1 mg/mL bovine serum albumin, 10 lg/mL leupeptin, 10 lg/mL
aprotinin, 10 lg/mL soybean trypsin inhibitor, 10 lg/mL benzami-
dine, 1 mM PMSF, 1 mM sodium vanadate) containing 0.5% Triton
X-100 and centrifuged at 12,000g for 15 min at 4 C. Lysates were
incubated with anti-V5 antibodies (1:100, Invitrogen) for 4 h at
4 C. Protein A-Sepharose beads (5 mg; Amersham Biosciences)
were added for 1 h at 4 C. Beads were washed three times and
resuspended in Laemmli sample buffer. Eluted immune complexes
were subjected to a 10% SDS–PAGE, then analyzed by Western
blotting using anti-V5 (1:50,000) or anti-phospho-T308 Akt
(1:5000; Upstate Biotechnology) antibodies. Mouse or rabbit True-
blot secondary antibodies (eBioscience) were used as secondary
antibodies and chemoluminescence was revealed using the
advanced ECL detection system (Amersham Biosciences).3. Results
3.1. Screening of the library of protein kinase inhibitors on adult
worms
The InhibitorSelect™ 96-Well Protein Kinase Inhibitor Library
I (Calbiochem) consists of eighty, well-characterized, cell-
permeable, potent and reversible protein kinase inhibitors. Most
of them are ATP-competitive. S. mansoni adult worm couples,
freshly recovered from infected hamsters, were maintained in the
culture conditions previously deﬁned (Vanderstraete et al.,
2013b), and we analyzed the level of male-female pairing and
egg laying following 24, 48 or 72 h of exposure to each inhibitor
added at a 10 lM ﬁnal concentration. Results (Table S1) indicated
a highly variable effect of each inhibitor on worms, ranging from a
complete (100%) inhibition of pairing and/or egg laying at 24 h to a
totally unaffected, as compared to untreated parasites, worm
behaviour following 72 h of culture. A selection was made of the
molecules that induced more or less profound alterations of pair-
ing and/or egg laying of treated worms during 72 h culture, and
for which potential target kinases were already characterized in
schistosomes (Table 1). These potential targets include receptor
(EGFR, FGFR and IR/IGFR) and cytosolic (Src, Abl, Fyn, Syk) tyrosine
kinases as well as serine/threonine kinases (TGF-bR, PKC) known
for their major functions in cell signaling and their importance in
schistosome development. Indeed, most of these kinases have
already been demonstrated to be druggable targets for parasites
and many authors have shown the impact of their targeting on
the viability and/or the reproduction of schistosomes (see refer-
ences in Table 1). In this study, we found additionally that three
Akt inhibitors contained in the library exerted a potent impairment
of pairing and egg-laying and we decided to undertake the study of
the S. mansoni Akt protein, in order to analyze its potential as a
novel drug target for schistosomes.3.2. Molecular cloning and structural characterization of SmAkt
Using tBLASTp analyzes, a putative nucleotide coding sequence
for S. mansoni Akt was identiﬁed in GenBank (XM_002578520.1). 50
and 30 UTR were determined with SmAkt encoding ESTs
(AM042871.1, CF497410.2, AA169931.1 and CF498818.1). The
complete nucleotide sequence of SmAkt was ampliﬁed by PCR
from total cDNA of adult worms. Its open reading frame encodes
a 586 amino acid protein with a predicted molecular weight of
67.8 kDa. Screening of S. mansoni genomic databases with the
SmAkt cDNA sequence indicated the presence of a single Akt gene
in the parasite. A single Akt gene has also been identiﬁed in other
Table 1
List of selected inhibitors that induce a signiﬁcant effect on adult worm pairing and/or egg laying and their potential kinase targets in S. mansoni.
Compound Pubchem ID Deleterious effect on Potential targets kinases in schistosome References
Pairing Egg laying
Compound 56 2857 + ++ EGF-R Dissous et al. (2014a)
EGFR/ErbB-2 inhibitor 9843206 +/ ++
EGFR inhibitor 9549299 + ++
EGFR/ErbB-2/ErbB-4 inhibitor 11566580  ++
PD 158780 4707 ++ ++
PD 174265 4709  +
AG 1478 2051  +
AG 1024 2044 ++ ++ IR/IGFR1-R Vanderstraete et al. (2013b)
IGF-1R inhibitor II 9549305 + ++
SU11652 5329103 ++ ++ FGF-R Hahnel et al. (2014)
Herbimycin A 16760502 ++ ++ Src Knobloch et al. (2006)
Beckmann et al. (2010)
Beckmann et al. (2011)
Src kinase inhibitor I 1474853  +
Flt-3 inhibitor III 11772958 + ++ Src/Abl
PDGF receptor tyrosine kinase inhibitor IV 9797370  ++ Src/Abl/Fyn
PP1 analog II, 1NM-PP1 5154691 + ++ Src/Fyn
Syk inhibitor 6419747  + Syk
Syk inhibitor III 672296 ++ ++ Syk/Src
TGF-b RI inhibitor III 16079009 ++ +/ TGF-bR Knobloch et al. (2007)
Chelerythrine chloride 72311 ++ ++ PKC Ludtmann et al. (2009)
Ressurreição et al. (2014)Gö 6976 3501 + +
Gö 6983 3499  +
PKCb inhibitor 6419755 ++ ++
Staurosporine, N-benzoyl- 16760627 ++ ++
Staurosporine, Streptomyces sp. 451705 ++ ++
PKCbII/EGFR inhibitor 6711154 ++ +/
Akt inhibitor IV 5719375 ++ ++ Akt
Akt inhibitor X 16760284 ++ ++
PDK1/Akt/Flt Dual Pathway inhibitor 5113385 ++ ++
Akt inhibitor V (=Triciribine) 290486  
Akt inhibitor VIII (=Akti1/2) 10196499 +/ +/
Inhibitors with a signiﬁcant inﬂuence on adult worm physiology were selected and classiﬁed in this list according to their speciﬁc targets, and their putative kinases already
identiﬁed in S. mansoni (see references). A scale of intensity of the action of each inhibitor on pairing and egg laying was deﬁned as follows. For pairing, ++ indicates that <50%
pairing is maintained at 24 h, + indicates <50% at 48 h and +/ indicates <50% of pairing at 72 h. For egg laying, ++ indicates a total number of eggs <10% of the eggs laid in
controls during 72 h of culture, + indicates a number comprised between 10% and 30% and +/ a number comprised between 30% and 50%.
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2013; Hemer et al., 2014) and in various insects (Drosophila mela-
nogaster, Anopheles gambiae, Aedes aegypti) (Andjelkovic et al.,
1995; Riehle and Brown, 2003). However, multiple copies are pres-
ent in vertebrate genomes and three different genes encode the
Akt1, Akt2 and Akt3 proteins which are highly similar in sequence
but have different functions in mammals (Hanada et al., 2004;
Cohen, 2013). Phylogenetic analysis conﬁrmed that SmAkt belongs
to the Akt/PKB family, which is distinct from the two other PKA and
PKC families of AGC kinases (Fig. S1). SmAkt groups with trema-
tode (Clonorchis sinensis) and cestode (Echinococcus, Hymenolepis)
Akt proteins on a branch separate from that of vertebrate and
insect Akt kinases. Sequence alignment of SmAkt with Akt proteins
from various species illustrates the important conservation of
these kinases (Fig. 1). Global identities between SmAkt and other
Akt proteins range from 45% to 56%. SmAkt was found to be more
similar to Akt1 than to Akt2 and Akt3 vertebrate proteins. As with
the other members of the Akt family, SmAkt possesses a conserved
(55–80% identity with others) N-terminal pleckstrin homology
(PH) domain (AA 106–208) involved in the binding of 3-phospho-
inositides and the recruitment of the protein to the membrane. The
central S/T-type protein kinase domain (AA 244–501) is also highly
conserved (68–75% identity with others) and contains the consen-
sus D385FG387 triplet corresponding to the ATP-binding domain as
well as the conserved residue T401 in the activation loop. In Akt
proteins, phosphorylation of this residue by PDK1 (phosphoinosi-
tide-dependent kinase-1) stimulates enzymatic activity whereas
additional phosphorylation by mTORC2 (mTOR complex 2) of a
conserved serine residue in the C-terminal hydrophobic motif(HM) of the regulatory domain, increases the Akt activity
(Sarbassov et al., 2005). This serine residue is present in SmAkt
at the position S565 inside of the conserved (F-X-X-F/Y-S/T-Y/F)
HM sequence F561EQFSF566. In SmAkt, as in cestode and insect
Akt proteins, an N-terminal extension precedes the PH domain.
This poorly conserved sequence does not contain any known
motifs; it is absent from vertebrate Akt proteins and its role is still
unknown.
3.3. Production of constitutively active mutants of SmAkt and kinase
inhibition
Molecular modeling and structure-based studies have indicated
that interactions between the PH and KD domains maintain the Akt
protein in a closed inactive conformation (Calleja et al., 2007, 2009)
(Fig. 2). In this closed conformation, PDK1 is unable to access and
phosphorylate T401 of SmAkt, until an upstream signal and PIP3
binding modiﬁes this conformation and allows Akt phosphoryla-
tion and activation (Fig. 2). It has been shown that constitutive
activation of Akt can result from mutations of residues at the inter-
face between PH and KD domains. Particularly, the E17K and L52R
mutations have been described in human cancers and such Akt1
somatic mutants are constitutively active, leading to oncogenic sig-
naling (Parikh et al., 2012).
In the present study, we have analyzed the impact of the ﬁve
Akt inhibitors contained in the InhibitorSelect™ library on the
physiology of S. mansoni adult worms (see Table S1). Three of them
were shown to considerably affect pairing and egg-laying of adult
worms (Table 1). In order to correlate these effects to an inhibition
Fig. 1. Protein sequence alignment of SmAkt with Akt proteins from other species. The SmAkt amino acid sequence was aligned using CLUSTAL W algorithm with Akt
sequences from Echinococcus multilocularis (EmAkt: CCW28045.1), Drosophila melanogaster (DmAkt1: Q8INB9.3), Anopheles gambiae (AgAkt: XP_003436044.1), Xenopus laevis
(XlAkt: AAG59601.1) and Homo sapiens (HsAkt1: AAL55732.1). Pleckstrin Homology (PH) domain is indicated in green, kinase domain (KD) in red and regulatory region in
blue. Stars indicate conserved residues (DFG motif of the ATP binding site, threonine and serine phosphorylation sites) implicated in phosphorylating activity. Arrows
indicated the PH domain residues (E117 and L150) involved in PH–KD interactions which maintain Akt kinases in inactive state. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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Akt inhibitor IV, A5: Triciribine, A6: Akt inhibitor VIII, A7: Akt
inhibitor X and A8: PDK1/Akt/Flt dual pathway inhibitor; see for-
mulas in Table S2) on constitutively active mutants of SmAkt cre-
ated by mutations of the conserved residues E117 and L150 of
SmAkt, exactly as in human Akt1 oncogenic active mutants. SmAkt
E117K and SmAkt L150R mutants were obtained by site-directed
mutagenesis of the SmAkt wild-type sequence contained in the
V5-pcDNA expression vector and their activity was monitored in
the Xenopus oocyte model. We have already demonstrated that
the Xenopus oocyte is a suitable model for expressing S. mansoni
proteins and for studying phosphorylating activity of protein
kinases (Vicogne et al., 2004). In stage VI oocytes, which are large
cells blocked in prophase I of meiosis I, the expression of any active
kinase triggers resumption of meiosis and induces Germinal Vesi-
cle BreakDown (GVBD), a process easily detected by eye. Following
injection of cRNAs and protein expression in oocytes, V5-tagged
SmAktWT, SmAkt E117K and SmAkt L150R proteins were immuno-
precipitated by anti-V5 antibodies and detected in Western blots
at a molecular weight of about 65 kDa (Fig. 3A). Results in
Fig. 3A also indicated that E117K and L150R mutations provoked
the constitutive activation of SmAkt and its phosphorylation on
the conserved T401 residue, which is recognized by anti-phospho
T308 human Akt antibodies. As a result of their activity, expression
of SmAkt E117K and SmAkt L150R proteins triggered meiosisresumption in oocytes monitored by GVBD (Fig. 3A and B). In these
experimental conditions, we analyzed the capacity of the ﬁve Akt
inhibitors (A4–8), tested previously on adult worms, to inhibit
resumption of meiosis in SmAkt E117K or SmAkt L150R-expressing
oocytes. Results in Fig. 3B show that all the inhibitors when used
at 10 lM ﬁnal concentration are able to completely inhibit the
phosphorylation of SmAkt mutants and their potential to induce
GVBD. Levels of inhibition were further shown to be dose-
dependent and to vary between the two Akt mutants. Globally,
SmAkt L150R appeared to be more sensitive than SmAkt E117K to
each inhibitor. All inhibitors, with the exception of A8, were
already active on SmAkt L150R at 1 lM decreasing GVBD levels to
more than 60% and they could induce 100% inhibition at 5 lM,
whereas the kinase activity of SmAkt E117K was partially
(30–50%) inhibited at 5 lM, with the exception of A4 where a total
inhibition was obtained. These data conﬁrmed the ability of A4, A5,
A6, A7 and A8 molecules to inhibit the recombinant SmAkt kinase
whereas both A5 and A6 molecules had no visible effects on adult
worms.
3.4. Dose-dependent effect of Akt inhibitors on adult worm pairing
in vitro
Results in Table S1 have shown that Triciribine (A5) and Akt
inhibitor VIII (A6) had a very low impact on pairing and egg-laying
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a potent deleterious effect on adult worms when added at 10 lM
in the culture medium, inhibiting totally worm pairing after 24 h
of contact with drugs. A kinetic study was performed to measure
the effect on schistosomes of these three inhibitors when used at
concentrations varying from 10 nM to 10 lM. Results (Fig. 4) con-
ﬁrmed the complete (A4 and A8) and almost complete (A7) inhibi-
tion of pairing after 24 h at the maximal dose of 10 lM. Moreover
they indicated a stronger effect of the A4 compound which still sig-
niﬁcantly (90%) inhibits worm pairing at 50 nM after 48 h whereas
the two other compounds A7 and A8 did not have any effect at this
dose even after 72 h. Results of egg counting were correlated with
pairing data. Within 72 h of incubation no egg was laid by worms
treated with 100 nM of A4 while 5 lM and 1 lM of A7 and A8 com-
pounds were respectively needed to block 100% egg laying (data
not shown).
3.5. Dose-dependent effect of Akt inhibitors on the viability of
schistosomula larvae
Further experiments were performed to measure the impact of
Akt inhibitors on the viability of S. mansoni larvae in vitro. One-day
old schistosomula were cultured for 3 days with different concen-
trations of the Akt inhibitors and parasite death was assessed by
loss of motility, tegument alterations and granular aspect, as in
previous studies (Vanderstraete et al., 2013b). At 10 lM concentra-
tion, we observed that A4, A7 and A8 compounds induced 100%
mortality in schistosomula cultures after 2 days whereas A6 was
less efﬁcient at this period and A5 without any effect on schisto-
somula viability at 72 h (Fig. S2). In a kinetic study, similar to that
performed on adult worms, we analyzed the effect of A4, A7 and A8
on schistosomula survival, using 50 nM to 10 lM doses. Results in
Fig. 5 indicated that A8 was the most efﬁcient compound towards
schistosomula. At 1 lM, 100% of schistosomula were killed at 24 h
with A8 whereas only 50% and 30% parasites were killed after 72 h
with this dose of A7 and A4, respectively. The compound A8
induced 50% mortality at 72 h at 50 nM, a concentration which is
for A4 and A7 almost inactive at this time period on schistosomula
viability.
4. Discussion and conclusion
Protein kinases are highly conserved molecules that play key
roles in the activation of many signaling pathways initiated by
external signals. They are involved in many biological processes
such as cell growth, proliferation and differentiation. In schisto-
somes, PKs have been shown to play major roles in development
and reproduction processes (Beckmann et al., 2012; Dissous
et al., 2014a). Targeting of diverse PKs was shown to affectTime (hours
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experiments).reproductive biology of parasites, as well as survival of adult worm
and/or schistosomula in vitro, supporting the hypothesis that PK
inhibitors are potential chemotherapeutics against schistosomiasis
(Dissous and Grevelding, 2011).
In this context, we have extended the research of novel anti-
schistosome drugs by screening the InhibitorSelect™ 96-Well Pro-
tein Kinase Inhibitor Library I (Calbiochem) and by analysing their
impact on S. mansoni worm pairing and egg laying in vitro. Most of
these PK inhibitors are ATP-competitive and are directed against a
large variety of kinases including receptor and soluble STKs or TKs.
First results indicated a highly variable effect of these molecules on
the parasite, some of them causing a total inhibition of pairing and
egg laying while others had no obvious effect on the general worm
physiology. Decrease of the level of pairing was in most cases asso-
ciated with inhibition of egg laying, but in some cases (particularly
with EGFR but also with GSK3 (Glycogen synthase kinase 3) and
Aurora inhibitors), egg laying was profoundly affected while worm
pairing was maintained, suggesting that the targeted kinases were
preferentially involved in gamete production. While the role of
EGFR in oogenesis and fertilization are well-known (Sundaram,
2006; Cheung et al., 2011), the functions of GSK3 in these processes
are not clearly established. However, different studies have
reported the role of GSK3 in oocyte maturation dependent on insu-
lin signaling (Acevedo et al., 2007; Uzbekova et al., 2009) and the
demonstration that HyGSK3 of Hydra vulgaris is overexpressed
during ovogenesis and spermatogenesis and that the inhibition of
its kinase activity stops sexual reproduction in Hydra (Rentzsch
et al., 2005), supports the hypothesis that GSK3 is important for
reproduction of schistosomes. Similarly, the function of Aurora
kinases is essential in mitosis and cell proliferation (Marumoto
et al., 2003) and this could explain the important effect of Aurora
inhibitors on schistosome egg laying.
Of the PK inhibitors identiﬁed in this work for their activity on
adult parasites, many have been shown to target speciﬁc TK
molecules, and particularly TKs for which schistosome homologs
were already highlighted for their role in development and
reproduction. Indeed, we conﬁrmed here the efﬁcacy of tyrphostin
AG1024, a potent inhibitory compound towards S. mansoni insulin
and VKR receptors which provoked alterations of reproductive
organs, and killed adult worms within 48 h at 10 lM
(Vanderstraete et al., 2013b). Tyrphostin AG1478, already shown
to inhibit SER but also SmVKR1 (Vanderstraete et al., 2013b),
reduced considerably the number of laid eggs (16% of control)
but as mentioned above it did not affect signiﬁcantly worm pairing.
Recently, SmFGFR-A/B were described for their potential roles in
gonad differentiation and reproduction. BIBF1120, a potent triple
inhibitor for FGFR, VEGFR and PDGFR affected the viability of adult
worms and provoked changes in gonad morphology and a drastic
decline of mitotically active cells in testes (Hahnel et al., 2014).)
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FGFR, VEGFR and PDGFR similarly to BIBF1120, also had a drastic
effect on pairing and egg laying. Three soluble TKs have been
shown to contribute to RTK signaling in schistosomes, SmTK3
(Src-like), SmTK4 (Syk-like) and SmTK6 (Src/Abl-like). The poten-
tial of Herbimycin, a Src-speciﬁc inhibitor, able to reduce mitotic
activity and egg production in female worms (Knobloch et al.,
2006) was conﬁrmed in this work by its effect on pairing and egg
laying, supporting the role of SmTK3 in the control of fecundity
(Kapp et al., 2004). Inhibition of SmTK4 by Syk inhibitors provoked
a decrease of egg laying, similar to that observed previously with
another Syk inhibitor, Piceatannol (Beckmann et al., 2010). The
Syk inhibitor III, which is active both on Syk and Src, was the most
efﬁcient on inhibition of pairing and egg laying, probably by its
dual effect on both kinases. Other compounds targeting more than
one CTKs exerted also a strong inhibitory effect on egg laying, sup-
porting the importance of TK signaling in reproductive activities of
schistosomes. Besides these TK enzymes, S/T kinases are funda-
mental for survival and reproductive function in schistosomes.
The strong effect of the TGFbR1 inhibitor III on pairing here con-
ﬁrms the major role of TGFb signaling in worm pairing and fertility
already observed by the use of the TbRI serine/threonine kinase
inhibitor (TRIKI) and the demonstration of its deleterious effect
on vitelline cell mitotic activity and egg production in female
worms (Knobloch et al., 2007; Buro et al., 2013). The PKC inhibitor
GF109203X was recently shown to inhibit worm pairing and egg
output (Ressurreição et al., 2014). Several other PKC inhibitory
compounds were tested in this study and their deleterious effect
on adult worms conﬁrmed the importance of PKC in S. mansoni
physiology and reproduction.
Additionally, anti-Akt compounds were identiﬁed for their
potent inhibitory action on pairing and egg laying, and this
prompted us to investigate on SmAkt and to study its sensitivity
to these inhibitors. Akt (or PKB) proteins belong to the PKA, PKG
and PKC (AGC) superfamily of S/T kinases. Akt mediates a variety
of physiological responses, including promotion of cell survival
and inhibition of apoptosis (Brazil et al., 2004). In mammals, the
Akt family consists of three members Akt1, Akt2 and Akt3. Akt1
plays a crucial role in tumorigenesis and is involved in cellular sur-
vival pathways, by inhibiting apoptosis and inducing protein syn-
thesis. Akt2 is an important signaling molecule in the insulin
signaling pathway, involved in glucose transport and Akt3 is prefer-
entially active in brain (Hanada et al., 2004). In most invertebrates,
a single Akt molecule is present, and a single gene encoding a pro-
tein homologous to Akt was found in S. mansoni genome databases
(Berriman et al., 2009). Phylogenetic analysis conﬁrmed that the
protein SmAkt groups with other vertebrate and invertebrate Akt/
PKB proteins on a branch distinct from those of PKA and PKC mem-
bers. SmAkt is close to Akt proteins from other platyhelminths and
its protein structure is highly conserved. SmAkt shares with othersthe domains which are essential for its kinase activity, ie the pleck-
strin homology (PH) domain for binding PI(3,4,5)P in membranes
and the conserved kinase domain containing an ATP binding motif
(D385FG387) and the two conserved phosphorylation sites T401 and
S565 required for its activation by upstream kinases. Similarly to
other invertebrate proteins, SmAkt contains a divergent N-terminal
extension (of about 100 AA) located upstream from the PH domain
and which is not found in vertebrate Akt proteins. In D. melanogas-
ter, splicing variants of the singleDmAkt gene can generate two pro-
teins differing by the presence or not of the ﬁrst 81 residues
composing this extension sequence (Andjelkovic et al., 1995). It is
conceivable that similar variants of Akt could exist in other species,
and particularly in S. mansoni. To our knowledge, a possible inci-
dence of this extra sequence in differential activities of DmAkt iso-
forms was not shown.
The PH domain of Akt plays a signiﬁcant role in recognition by
upstream kinases since it acts as an inhibitor of phosphorylation of
T308 of human Akt by masking this residue from PDK1. Intramolec-
ular interactions between PH domain-kinase domain (KD) main-
tain Akt in an inactive conformation and it has been shown that
destabilizing interdomain contacts results in constitutive activa-
tion of Akt in human cancers. E17K and L52R mutations in the PH
domain of Akt found in human cancers generate constitutively
active Akt mutants. Two-hybrid assays using mutated Akt PH and
wild type KD constructs have conﬁrmed that PH mutants were
deﬁcient in PH–KD interaction (Parikh et al., 2012). As human E17
and L52 residues are conserved, respectively, at positions 117 and
150 in SmAkt, we generated by site-directed mutagenesis E117K
and L150R SmAkt mutants. Effectively, both mutated proteins (but
not wild-type Akt) were shown to be spontaneously active when
expressed in Xenopus oocyte and they were further used in inhibi-
tion assays to test anti-Akt compounds on their activity. The ﬁve
Akt inhibitors contained in the library were shown to inhibit (when
used at 10 lM) 100% of the capacity of E117K and L150R SmAkt
mutants to be phosphorylated and to induce oocyte maturation.
However, as the mode of action on Akt differs signiﬁcantly for each
Akt inhibitor, and specially that some of them like A4 and A8 have
also an activity on the upstream kinase PDK1, these results only
indicated that the ﬁve Akt inhibitors were active on the Akt path-
way, by direct or indirect inhibition of the Akt enzyme. Indeed, if
A5, A6 and A7 are selective for Akt (Yang et al., 2004; Barnett
et al., 2005; Thimmaiah et al., 2005), A4 and A8 are known to also
target Akt upstream kinases such as PDK1 (Kau et al., 2003; Zeng
et al., 2006) and could as well inhibit Akt activity by this way. A
putative Ser/Thr kinase similar to PDK1 is present in the S. mansoni
genome (CAZ 36594) (Protasio et al., 2012) susceptible to partici-
pate to the PI3K/Akt pathway in schistosomes. Thus, these data
conﬁrmed the high conservation of SmAkt with other Akt proteins
and the possibility to target SmAkt pathway with Akt inhibitors in
living parasites.
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noticed that only three out of the ﬁve Akt inhibitors reduced at
10 lM worm pairing and egg laying. The ﬁve anti-Akt molecules
have been classiﬁed as cell permeable by the manufacturer, and
it is difﬁcult to know whether the inefﬁciency of Triciribine (A5)
and Akt inhibitor VIII (A6) results from the limited permeability
or from the instability of the molecules in culture medium. Kinetic
studies made to compare the efﬁcacy of A4, A7 and A8 on adult
schistosomes conﬁrmed complete (for A4 and A8) and almost com-
plete (for A7) inhibition of worm pairing as soon as 24 h at 10 lM.
The A4 compound appeared to be the most active on adult worms,
since it remained highly efﬁcient at 50 nM after 48 h whereas the
two other compounds A7 and A8 had no more activity at this dose.
As on adult parasites, A4, A7 and A8 were the most toxic com-
pounds on schistosomula, able to kill 100% of larvae within 2 days
at 10 lMwhereas the toxicity of A6 was limited and A5 was totally
inefﬁcient on this parasite stage. Interestingly, the most active
compound on schistosomula was A8 and not A4 as on adult worms.
A8 was able to kill 50% of schistosomula within 3 days at 50 nM
whereas A4 and A7 had no activity at this dose. Again, it is difﬁcult
to explain the stronger effect of A8 compared to A4 and A7 on lar-
vae, but its PDK1/Akt/Flt dual pathway inhibitory action (Zeng
et al., 2006) might reinforce its lethal activity towards parasite
larvae.
Akt/PKB is a downstream target of many RTKs and a central
player at the crossroads of many metabolic pathways activated
in response to growth factors and primarily to insulin. We have
previously demonstrated the importance of VKR and insulin-like
receptor signaling in the reproductive activities of schistosomes
and the capacity of VKR to activate the PI3K/Akt pathway has been
conﬁrmed in the model of Xenopus oocytes (Vanderstraete et al.,
2014). Preliminary experiments (results not shown) have indi-
cated that the targeting of SmAkt by RNA interference in adult
worms induced phenotypes similar to those observed in parasites
interfered for SmVKR, showing important morphological changes
in female worms, with a disorganization of the ovary and a defect
of egg formation (Vanderstraete et al., 2014). In insects, insulin
pathway and particularly its most positive regulator the Akt
kinase, have been shown to directly participate in reproductive
processes in dipterans (Riehle and Brown, 2003) and in hymenopt-
erans (Okada et al., 2010). In this study, we have shown that bis-
indolylmaleimide I, which targets and inhibits GSK3, the major
substrate of Akt demonstrated to contribute to gametogenesis
(Rentzsch et al., 2005), also stopped egg laying in schistosomes.
Altogether, these data strongly suggest that SmAkt, situated at
the junction of diverse essential signaling pathways, acts as a
key regulator of reproduction processes in schistosomes, and that
it represents a novel interesting drug target for schistosomiasis
control. Further structure-based activity studies are now needed
to improve our knowledge of SmAkt and to design parasite-
speciﬁc molecules that could be used for the development of novel
chemotherapies.Conﬂict of interest
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